Second-order map
Exploratory — reasoned, hypothetical relationships for research, not investment advice.
- LLYCatalyst
Eli Lilly and Company
Q2 2026 results and first full-quarter Foundayo (orforglipron) read reframe GLP-1 competition around oral delivery, triggering an industry-wide wave of NDA filings and formulation work
- CERTSpotlight subject
Certara, Inc.
Primary subject: as oral/next-gen GLP-1 filings surge concurrently, its biosimulation, model-informed drug development, and expedited pharmacometrics regulatory submission service sit at the formulation-to-filing bottleneck every competing sponsor must activate
- SLP
Simulations Plus, Inc.
If model-informed submissions become table stakes, a parallel biosimulation/PBPK-modeling vendor could absorb overflow formulation-optimization demand the leader cannot clear
- SDGR
Schrodinger, Inc.
Physics-based molecular simulation could feed the upstream design of next-gen oral small-molecule GLP-1 candidates whose later-stage work flows into regulatory modeling
- MEDP
Medpace Holdings, Inc.
A concurrent filing wave implies more bridging/formulation clinical studies, pulling in a mid-size CRO that runs the trials feeding the submission packages
- VEEV
Veeva Systems Inc.
If NDA volume rises across sponsors, the regulatory-content and submission-management software layer that organizes those filings sees broader seat/module adoption
- CTLT
Catalent / oral-dose CDMO capacity
Direct operational beneficiary: a shift toward oral GLP-1 formulations needs tablet/capsule formulation and fill-finish manufacturing scale-up that peptide-injection lines cannot supply
Specialty oral-absorption excipient / permeation-enhancer supplier
If oral peptide/small-molecule bioavailability is the technical hurdle, makers of absorption-enhancing excipients become a hidden input constraint
- WST
West Pharmaceutical Services, Inc.
Even in an oral-pivot narrative, a supplier of drug-contact packaging/containment components could gain as new formats still require qualified primary packaging
- DHR
Danaher Corporation
Scaled formulation and analytical characterization work raises demand for bioprocess/lab instrumentation and consumables across the filer cohort
- TMO
Thermo Fisher Scientific Inc.
As a CDMO and lab-supply backbone, broader multi-sponsor development activity lifts analytical-testing and manufacturing-services utilization
- IQV
IQVIA Holdings Inc.
Direct beneficiary: concurrent GLP-1 programs across many sponsors expand demand for clinical-development services, real-world evidence, and regulatory analytics that support each filing
- ICLR
ICON plc
A broad filing wave can exceed one CRO's capacity, routing late-stage and bioequivalence trial work to a peer global CRO
- CRL
Charles River Laboratories International, Inc.
New-formulation and next-gen candidates still require preclinical safety/tox work, feeding an early-stage research-services provider upstream of the filings
- RDNT
RadNet, Inc.
Highly lateral: if metabolic-drug adoption and competing trials expand, imaging-endpoint and diagnostic-scan volume tied to cardiometabolic monitoring could see incremental demand
Take it further
Copy the analysis below into your own AI tool to pressure-test the reasoning and push it further.
Today's crowd trade is straightforward — investors will be closely watching the sales performance of Mounjaro and Zepbound when Eli Lilly reports its second-quarter 2026 results alongside the first commercial read on Foundayo (orforglipron), which launched in April and receives its first full-quarter commercial update today. The headline machinery around Eli Lilly is loud, but the durable second-order read belongs one step removed — in the biosimulation and regulatory science infrastructure that every competing GLP-1 filer must now activate. Oral delivery, not just higher numbers, is now a primary axis of competition , which means a wave of new NDA filings and formulation optimization work is not a distant possibility but an imminent workflow burden across the industry. Certara sits precisely at that bottleneck: from molecule to market, Certara integrates science, technology, strategic and regulatory expertise, and navigates complex regulatory landscapes with AI-driven tools while reducing development risk through predictive science and model-informed strategies . Certara recently launched an expedited Pharmacometrics regulatory submission service that cuts submission timelines in half — a capability that is structurally more valuable in a race where multiple sponsors are filing oral and next-generation GLP-1 formulations concurrently than in any single-drug cycle.